Background ThoraQuik is a device with a unique design incorporating an aspiration port and one-way valve controlled by a three-way tap, fit for purpose for the treatment of pneumothorax and pleural effusion. Its use, safety and efficacy were evaluated in a prospective observational trial.
Methods Stage 1: The safety and ability of the device to penetrate the chest wall and the ease of use were evaluated in patients undergoing thoracoscopic procedures by introducing the device at a second port site under vision. Stage 2: The device was evaluated on patients with pneumothorax and pleural effusion. Clinical and radiological improvement were endpoints and operator feedback was evaluated.
Results Phase 1: 10 patients (mean age: 48.5 years (18–76 years) six men) were studied between May 2005 and March 2007. Satisfactory penetration of the chest wall and safe entry in the pleural space was achieved. Phase 2: 20 patients (mean age: 59 years (24–81 years) 13 men) were recruited between May 2007 and May 2008. 10 patients presented with pneumothorax (tension pneumothorax, n=1) and 10 had pleural effusions. One patient withdrew consent and another patient was withdrawn as there was no fluid on trial aspiration. Of the 18 who completed the study, 10/18 had partial and 7/18 patients had complete resolution with no change in one. The qualitative assessments of the ThoraQuik in terms of ease of use and utility were positive.
Conclusions ThoraQuik achieves satisfactory penetration of the chest wall. It was safe and easy to use to manage pneumothoraces and pleural effusions.
- emergency department management
- needle decompression
- pleural effusion
- Accepted 25 June 2010
Statistics from Altmetric.com
Funding The study was supported by the Department of Thoracic Surgery and the devices were provided free of cost by MDI Ltd.
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the East Birmingham Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
↵* PW was attached to MDI at the time of the study.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.